- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Peter McAllister Explains the Economic Benefits of Migraine Prevention
Migraine accounts for many billions of dollars in direct and indirect health care costs, said Peter McAllister, MD, a neurologist, board certified headache specialist, and medical director of the New England Institute for Neurology and Headache.
Migraine accounts for many billions of dollars in direct and indirect health care costs, said Peter McAllister, MD, a neurologist, board certified headache specialist, and medical director of the New England Institute for Neurology and Headache.
Transcript:
The American Journal of Managed Care® (AJMC®): What are some of the economic benefits of migraine prevention?
Dr. McAllister: When you look at the numbers for migraine, it is huge. It's in the many billions of dollars in health care costs and utilization. That can be divided into two buckets, really. There's direct health care costs related to migraine, and that is going to the doctor, going to the emergency department, getting migraine medication. But the much bigger slice of the pie is the indirect costs. That is the missing work, what we call absenteeism, or actually showing up for work, but being so shot from your migraine, that you have difficulty focusing, you're inefficient, and that costs the system billions of dollars. If you can get people to have a whole lot less migraine attacks per month, and then per year, etc., you're going to decrease those indirect costs as well as decrease the direct costs substantially.
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More
